| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
|---|---|
| CARP | carbonic anhydrase-related polypeptide |
| CAII | Carbonic Anhydrase II |
|---|---|
| CA | Carbonic anhydrase |
| CAH | Carbonic anhydrase |
| CA B | Carbonic anhydrase B |
| CA III | Carbonic anhydrase III |
| sulfanilazocarbonic anhydrase | <enzyme> Derivative of carbonic anhydrase (EC 4.2.1.1) Registry number: EC 4.2.1.- (26 Jun 1999) |
|---|
| anhydrase | <enzyme> An enzyme that catalyses the removal of water from a compound; most such enzymes are now known as hydrases, hydro-lyases, or dehydratases. Carbonic anhydrase, a zinc-containing enzyme that catalyses the interconversion of CO2 with HCO3- and H+. There are at least seven human isozymes that appear predominantly in red blood cells, secretory tissues, muscle, etc. A deficiency of carbonic anhydrase II can result in osteopetrosis and metabolic acidosis. The inhibition of carbonic anhydrase IV and possibly carbonic anhydrase II by sulfonamides is a current therapy in the treatment of glaucoma. Synonym: carbonate dehydratase, carbonate hydro-lyase. (05 Mar 2000) |
|---|---|
| carbonic anhydrase II deficiency syndrome | <syndrome> An inherited deficiency of carbonic anhydrase II that results in osteopetrosis and metabolic acidosis. Synonym: osteopetrosis with renal tubular acidosis. (05 Mar 2000) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| carbonic anhydrase inhibitors | A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrase (carbonate dehydratase). Although their therapeutic use as diuretics is not frequent, they are used in clinical conditions where alkalinization of the urine is beneficial. Their most frequent application is in the reduction of intra-ocular pressure in the treatment of glaucoma. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|